NX-0479 (GS-6791)

About Nurix Therapeutics

Nurix Therapeutics is focused on discovering, developing, and commercializing small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Its core DELigase platform integrates expertise in E3 ligases, ubiquitination, and medicinal chemistry to create targeted protein degraders and inhibitors. The company has established strategic collaborations with major pharmaceutical partners like Gilead and Sanofi, and is progressing a robust pipeline of drug candidates, including its lead BTK degrader NX-5948 and CBL-B inhibitor NX-1607, through clinical development.

Therapeutic Areas

Other Oncology (undisclosed) Drugs